Athenahealth (ATHN) 10-Q 30 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 28, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	ATHN
Entity Registrant Name	ATHENAHEALTH INC
Entity Central Index Key	1131096
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		38,553,342

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$32,593	$73,787
Marketable securities	27,160	40,950
Accounts receivable, net	118,656	121,710
Deferred tax asset, net	13,614	0
Prepaid expenses and other current assets	26,931	22,627
Total current assets	218,954	259,074
Property and equipment, net	282,837	271,552
Capitalized software costs, net	85,305	56,574
Purchased intangible assets, net	144,249	139,422
Goodwill	230,147	198,049
Investments and other assets	7,455	7,327
Total assets	968,947	931,998
Current liabilities:
Accounts payable	9,982	9,410
Accrued compensation	41,164	71,768
Accrued expenses	43,377	37,033
Line of credit	0	35,000
Long-term debt	0	15,000
Deferred revenue	34,283	28,949
Deferred tax liability, net	0	8,449
Total current liabilities	128,806	205,609
Deferred rent, net of current portion	22,281	19,412
Line of credit	95,000	0
Long-term debt, net of current portion	170,000	158,750
Deferred revenue, net of current portion	54,892	54,473
Long-term deferred tax liability, net	25,576	10,417
Other long-term liabilities	8,640	8,214
Total liabilities	505,195	456,875
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.01 par value: 5,000 shares authorized; no shares issued and outstanding at March 31, 2015 and December 31, 2014	0	0
Common stock, $0.01 par value: 125,000 shares authorized; 39,766 shares issued and 38,488 shares outstanding at March 31, 2015; 39,402 shares issued and 38,124 shares outstanding at December 31, 2014	398	395
Additional paid-in capital	449,415	443,259
Treasury stock, at cost, 1,278 shares	-1,200	-1,200
Accumulated other comprehensive income	15,490	24,188
Retained (deficit) earnings	-351	8,481
Total stockholders’ equity	463,752	475,123
Total liabilities and stockholders’ equity	$968,947	$931,998

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	39,766,000	39,402,000
Common stock, shares outstanding	38,488,000	38,124,000
Treasury stock, shares	1,278,000	1,278,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenue:
Business services	$197,763	$154,502
Implementation and other	8,671	8,533
Total revenue	206,434	163,035
Expense:
Direct operating	84,557	72,148
Selling and marketing	53,365	43,227
Research and development	23,728	15,155
General and administrative	36,212	29,357
Depreciation and amortization	20,352	14,249
Total expense	218,214	174,136
Operating loss	-11,780	-11,101
Other (expense) income:
Interest expense	-1,059	-1,265
Other income (expense)	44	-171
Total other expense	-1,015	-1,436
Loss before income tax benefit	-12,795	-12,537
Income tax benefit	3,963	4,482
Net loss	($8,832)	($8,055)
Net (loss) income per share - Basic (in dollars per share)	($0.23)	($0.21)
Net (loss) income per share - Diluted (in dollars per share)	($0.23)	($0.21)
Weighted average shares used in computing net loss per share:
Basic (shares)	38,278	37,484
Diluted (shares)	38,278	37,484

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net loss	($8,832)	($8,055)
Other comprehensive (loss) income
Unrealized (loss) gain on securities, net of tax of $5,194 and ($27,534) for the three months ended March 31, 2015 and 2014, respectively	-8,596	45,636
Unrealized (loss) gain on change in fair value of interest rate swap, net of tax of $140 and ($8) for the three months ended March 31, 2015 and 2014, respectively	-231	12
Foreign currency translation adjustment	129	103
Total other comprehensive (loss) income	-8,698	45,751
Comprehensive (loss) income	($17,530)	$37,696

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Unrealized gain (loss) on securities, tax	$5,194	($27,534)
Unrealized (loss) gain on interest rate derivative, tax	$140	($8)

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($8,832)	($8,055)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	26,541	21,459
Deferred income tax	-4,219	-4,605
Stock-based compensation expense	15,874	12,351
Other reconciling adjustments	102	171
Changes in operating assets and liabilities:
Accounts receivable, net	4,183	325
Prepaid expenses and other current assets	-4,491	-1,627
Other long-term assets	58	-945
Accounts payable	1,139	3,913
Accrued expenses and other long-term liabilities	6,683	2,951
Accrued compensation	-30,027	-13,529
Deferred revenue	3,314	1,255
Deferred rent	2,599	402
Net cash provided by operating activities	12,924	14,066
CASH FLOWS FROM INVESTING ACTIVITIES:
Capitalized software development costs	-38,492	-11,057
Purchases of property and equipment	-22,815	-5,325
Payments on acquisitions, net of cash acquired	-40,165	0
Change in restricted cash	0	2,806
Net cash used in investing activities	-101,472	-13,576
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under stock plans and warrants	6,287	9,000
Taxes paid related to net share settlement of stock awards	-15,310	-19,464
Proceeds from line of credit	60,000	0
Payments for long-term debt	-3,750	-3,750
Net cash provided by (used in) financing activities	47,227	-14,214
Effect of exchange rate changes on cash and cash equivalents	127	-15
Net decrease in cash and cash equivalents	-41,194	-13,739
Cash and cash equivalents at beginning of period	73,787	65,002
Cash and cash equivalents at end of period	32,593	51,263
Non-cash transactions
Property, equipment and purchased software recorded in accounts payable and accrued expenses	9,557	3,753
Non-cash leasehold improvements	105	0
Taxes to be paid related to net share settlement of stock units in accrued compensation	0	2,209
Additional disclosures
Cash paid for interest, net	252	1,474
Cash (refunded) paid for taxes	$136	($761)

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION
	General – The accompanying unaudited condensed consolidated financial statements have been prepared by athenahealth, Inc. (the “Company” or “we” or “our”) in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the financial position as of March 31, 2015, the results of operations for the three months ended March 31, 2015, and 2014, and cash flows for the three months ended March 31, 2015, and 2014. The results of operations for the three month period ended March 31, 2015 are not necessarily indicative of the results to be expected for the full year. When preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material.
	We consider events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date of issuance of these financial statements.
	Related Party Transactions – We have a long-term investment in a vendor. The total expense related to this vendor for the three months ended March 31, 2015, and 2014 was $4.3 million and $1.3 million, respectively, and the total amount payable to this vendor at March 31, 2015 and December 31, 2014 was $1.6 million and $1.3 million, respectively.
	New Accounting Pronouncements – In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-03, Simplifying the Presentation of Debt Issuance, which changes the presentation of debt issuance costs in financial statements. Under this guidance, an entity will present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. We have evaluated this ASU and determined that its adoption will not have a material effect on our financial position or earnings. This guidance is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted for all entities for financial statements that have not been previously issued.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the current revenue recognition guidance, including industry-specific guidance. In addition, the ASU provides guidance on accounting for certain revenue-related costs including, but not limited to, when to capitalize costs associated with obtaining and fulfilling a contract. ASU 2014-09 provides companies with two implementation methods. Companies can choose to apply the standard retrospectively to each prior reporting period presented (full retrospective application) or retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). We are currently in the process of evaluating this new guidance. This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In April 2015, the FASB proposed a one-year delay in the effective date of the standard to January 1, 2018, with an option that would permit companies to adopt the standard as early as the original effective date. Early adoption prior to the original effective date is not permitted.
	Debt Commitment Letter – On March 6, 2015, we entered into a commitment letter for a new senior credit facility (the “2015 Senior Credit Facility”) which will include a revolving facility and a term loan facility and replace our existing Senior Credit Facility. The contemplated 2015 Senior Credit Facility will have no current payment obligations and, as such, we have excluded our existing debt obligations from current liabilities. We anticipate closing on the 2015 Senior Credit Facility during the three months ending June 30, 2015.

ACQUISITIONS

ACQUISITIONS	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
ACQUISITIONS	ACQUISITIONS
	webOMR
	On January 23, 2015, we signed an agreement to purchase a suite of internally-developed clinical applications and an electronic health record system from Beth Israel Deaconess Medical Center, Inc. (“BIDMC”) referred to as webOMR for $22.0 million in cash. The agreement also provides for up to an additional $18.0 million in contingent payments upon achievement of certain milestones in the future. In connection with the purchase of the webOMR technology, the parties also entered into a two-year collaboration agreement under which BIDMC will provide ongoing consultation services with respect to the webOMR technology and provide one of its facilities as a testing site for a new inpatient service offering. We purchased webOMR to accelerate our entry into the inpatient market.
	RazorInsights
	On January 13, 2015, we acquired Razor Insights, LLC (“RazorInsights”), a provider of cloud-based billing and electronic health record (“EHR”) software services to rural and community hospitals, for $40.2 million in cash. We acquired RazorInsights for the assembled workforce, technology, customer base and to accelerate our entrance into serving the inpatient segment. The fair value of net assets acquired was $8.1 million, including purchased intangible assets of $7.0 million related to Technology acquired and $4.0 million related to customer relationships. The $32.1 million excess of purchase consideration over the fair value of net assets acquired is allocated to goodwill, which is deductible for U.S. income tax purposes. We incurred transaction costs in connection with the acquisition of $0.3 million, which are included in general and administrative expenses.
	The fair values assigned to assets acquired and liabilities assumed were based on information that was available as of the date of the acquisition. Certain items, such as the working capital adjustments to the purchase price and the value of the purchased intangible assets, are subject to change as additional information is received about facts and circumstances that existed at the date of acquisition.

NET_LOSS_INCOME_PER_SHARE

NET (LOSS) INCOME PER SHARE	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
NET (LOSS) INCOME PER SHARE	NET (LOSS) INCOME PER SHARE
	Basic net (loss) income per share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted average number of common shares outstanding and potentially dilutive securities outstanding during the period under the treasury stock method. Potentially dilutive securities include stock options, restricted stock units, and shares to be purchased under the employee stock purchase plan. Under the treasury stock method, dilutive securities are assumed to be exercised at the beginning of the periods and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Securities are excluded from the computations of diluted net (loss) income per share if their effect would be anti-dilutive to earnings per share; therefore, in periods of net loss, shares used to calculate basic and dilutive net loss per share are equivalent.
	The following table reconciles the weighted average shares outstanding for basic and diluted net loss per share for the periods indicated:
		Three Months Ended March 31,
		2015			2014
	Net loss	$	(8,832	)	$	(8,055	)
	Weighted average shares used in computing basic and diluted net loss per share	38,278			37,484
	Net loss per share – basic and diluted	$	(0.23	)	$	(0.21	)

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS
	As of March 31, 2015 and December 31, 2014, the carrying amounts of cash and cash equivalents, receivables, accounts payable, and accrued expenses approximated their estimated fair values because of the short-term nature of these financial instruments. As of March 31, 2015, we had $170.0 million outstanding on our term loan facility and $95.0 million outstanding on our revolving credit facility. As of December 31, 2014, we had $173.8 million outstanding on our term loan facility and $35.0 million outstanding on our revolving credit facility. The facility carries a variable interest rate set at current market rates, and as such the carrying value approximates fair value.
	Our More Disruption Please (“MDP”) Accelerator portfolio is a program designed to cultivate heath care information technology start-ups and expand services offered to our physician network. Our investments of $0.8 million as of March 31, 2015 and December 31, 2014 are in the form of short-term convertible notes receivable, and are included in prepaid expenses and other current assets on our Condensed Consolidated Balance Sheets. At March 31, 2015, as there is no indication of performance risk and no conversion is currently contemplated, we estimate that the fair value of these notes receivable approximate cost, based on inputs including the original transaction price, our own recent transactions in the same or similar instruments, completed or pending third-party transactions in the underlying investments, subsequent rounds of financing, and changes in financial ratios or cash flows (Level 3).
	Marketable equity securities are valued using a market approach based upon the quoted market prices of identical instruments when available or other observable inputs such as trading prices of identical instruments in inactive markets or similar securities.
	Our interest rate swap agreement was designed to manage exposure to interest rates on our variable rate indebtedness. We have designated the interest rate swap agreement as a cash flow hedge. For the three months ended March 31, 2015, no amount was recognized in earnings for our interest rate swap. There was no ineffectiveness associated with the interest rate swap during the three months ended March 31, 2015, nor was any amount excluded from ineffectiveness testing. We do not expect that any of the $0.4 million of pre-tax unrealized losses included in accumulated other comprehensive income at March 31, 2015, will be reclassified into earnings within the next 12 months. This amount will vary due to fluctuations in interest rates. We are exposed to credit loss in the event of non-performance by the swap counterparty.
	The estimated fair value of our interest rate swap agreement with a certain financial institution at March 31, 2015 and December 31, 2014 was a liability of $0.6 million and $0.2 million, respectively, based on inputs other than quoted prices that are observable for the interest rate swap (Level 2). Inputs include present value of fixed and projected floating rate cash flows over the term of the swap contract.
	The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, and fair values determined by Level 2 inputs utilize quoted prices (unadjusted) in inactive markets for identical assets or liabilities obtained from readily available pricing sources for similar instruments. The fair values determined by Level 3 inputs are unobservable values which are supported by little or no market activity. It is our policy to recognize transfers between levels of the fair value hierarchy, if any, at the end of the reporting period; however, there have been no such transfers during any of the periods presented.
			Fair Value Measurements as of March 31, 2015, Using
			Level 1		Level 2			Level 3		Total
	Available-for-sale investments:
	Marketable equity securities		$	27,160	$	—		$	—	$	27,160
	Debt securities
	MDP Accelerator portfolio		$	—	$	—		$	750	$	750
	Total assets		$	27,160	$	—		$	750	$	27,910
	Interest rate swap liability (a)		$	—	$	(615	)	$	—	$	(615	)
	Total liabilities		$	—	$	(615	)	$	—	$	(615	)
			Fair Value Measurements as of December 31, 2014, Using
			Level 1		Level 2			Level 3		Total
	Available-for-sale investments:
	Marketable equity securities		$	40,950	$	—		$	—	$	40,950
	Debt securities
	MDP Accelerator portfolio		$	—	$	—		$	750	$	750
	Total assets		$	40,950	$	—		$	750	$	41,700
	Interest rate swap liability (a)		$	—	$	(244	)	$	—	$	(244	)
	Total liabilities		$	—	$	(244	)	$	—	$	(244	)
	(a)	Recorded in other long-term liabilities on the Condensed Consolidated Balance Sheets.
	The following table presents our financial instruments measured at fair value using unobservable inputs (Level 3) as of March 31, 2015:
			Fair Value Measurements Using Unobservable Inputs (Level 3)
			31-Mar-15
	Balance, January 1, 2015		$	750
	Reductions		—
	Additions		—
	Balance, March 31, 2015		$	750

INVESTMENTS

INVESTMENTS	3 Months Ended
	Mar. 31, 2015
Investments [Abstract]
INVESTMENTS	INVESTMENTS
	We had the following available-for-sale securities as of March 31, 2015:
		Cost		Gross		Fair Value
				Unrealized Gain
	Marketable equity securities	$	1,100	$	26,060	$	27,160
	We had the following available-for-sale securities as of December 31, 2014:
		Cost		Gross		Fair Value
				Unrealized Gain
	Marketable equity securities	$	1,100	$	39,850	$	40,950

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES
	We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment discrimination claims and challenges to our intellectual property. We believe that we have adequate legal defenses and that the likelihood of a loss contingency relating to the ultimate disposition of any of these claims is remote. When the likelihood of a loss contingency becomes at least reasonably possible with respect to any of these disputes, or, as applicable in the future, if there is at least a reasonable possibility that a loss exceeding amounts already recognized may have been incurred, we will revise our disclosures in accordance with the relevant authoritative guidance.
	Additionally, we will accrue a liability for loss contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. We will review these accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations, or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.

BASIS_OF_PRESENTATION_Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	New Accounting Pronouncements – In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-03, Simplifying the Presentation of Debt Issuance, which changes the presentation of debt issuance costs in financial statements. Under this guidance, an entity will present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. We have evaluated this ASU and determined that its adoption will not have a material effect on our financial position or earnings. This guidance is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted for all entities for financial statements that have not been previously issued.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the current revenue recognition guidance, including industry-specific guidance. In addition, the ASU provides guidance on accounting for certain revenue-related costs including, but not limited to, when to capitalize costs associated with obtaining and fulfilling a contract. ASU 2014-09 provides companies with two implementation methods. Companies can choose to apply the standard retrospectively to each prior reporting period presented (full retrospective application) or retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). We are currently in the process of evaluating this new guidance. This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In April 2015, the FASB proposed a one-year delay in the effective date of the standard to January 1, 2018, with an option that would permit companies to adopt the standard as early as the original effective date. Early adoption prior to the original effective date is not permitted.
	Debt Commitment Letter – On March 6, 2015, we entered into a commitment letter for a new senior credit facility (the “2015 Senior Credit Facility”) which will include a revolving facility and a term loan facility and replace our existing Senior Credit Facility. The contemplated 2015 Senior Credit Facility will have no current payment obligations and, as such, we have excluded our existing debt obligations from current liabilities. We anticipate closing on the 2015 Senior Credit Facility during the three months ending June 30, 2015.

NET_LOSS_INCOME_PER_SHARE_Tabl

NET (LOSS) INCOME PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table reconciles the weighted average shares outstanding for basic and diluted net loss per share for the periods indicated:
		Three Months Ended March 31,
		2015			2014
	Net loss	$	(8,832	)	$	(8,055	)
	Weighted average shares used in computing basic and diluted net loss per share	38,278			37,484
	Net loss per share – basic and diluted	$	(0.23	)	$	(0.21	)

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, and fair values determined by Level 2 inputs utilize quoted prices (unadjusted) in inactive markets for identical assets or liabilities obtained from readily available pricing sources for similar instruments. The fair values determined by Level 3 inputs are unobservable values which are supported by little or no market activity. It is our policy to recognize transfers between levels of the fair value hierarchy, if any, at the end of the reporting period; however, there have been no such transfers during any of the periods presented.
			Fair Value Measurements as of March 31, 2015, Using
			Level 1		Level 2			Level 3		Total
	Available-for-sale investments:
	Marketable equity securities		$	27,160	$	—		$	—	$	27,160
	Debt securities
	MDP Accelerator portfolio		$	—	$	—		$	750	$	750
	Total assets		$	27,160	$	—		$	750	$	27,910
	Interest rate swap liability (a)		$	—	$	(615	)	$	—	$	(615	)
	Total liabilities		$	—	$	(615	)	$	—	$	(615	)
			Fair Value Measurements as of December 31, 2014, Using
			Level 1		Level 2			Level 3		Total
	Available-for-sale investments:
	Marketable equity securities		$	40,950	$	—		$	—	$	40,950
	Debt securities
	MDP Accelerator portfolio		$	—	$	—		$	750	$	750
	Total assets		$	40,950	$	—		$	750	$	41,700
	Interest rate swap liability (a)		$	—	$	(244	)	$	—	$	(244	)
	Total liabilities		$	—	$	(244	)	$	—	$	(244	)
	(a)	Recorded in other long-term liabilities on the Condensed Consolidated Balance Sheets.
Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	The following table presents our financial instruments measured at fair value using unobservable inputs (Level 3) as of March 31, 2015:
			Fair Value Measurements Using Unobservable Inputs (Level 3)
			31-Mar-15
	Balance, January 1, 2015		$	750
	Reductions		—
	Additions		—
	Balance, March 31, 2015		$	750

INVESTMENTS_Tables

INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Investments [Abstract]
Schedule of Available-for-sale Securities Reconciliation	We had the following available-for-sale securities as of March 31, 2015:
		Cost		Gross		Fair Value
				Unrealized Gain
	Marketable equity securities	$	1,100	$	26,060	$	27,160
	We had the following available-for-sale securities as of December 31, 2014:
		Cost		Gross		Fair Value
				Unrealized Gain
	Marketable equity securities	$	1,100	$	39,850	$	40,950

BASIS_OF_PRESENTATION_Narrativ

BASIS OF PRESENTATION - Narrative (Details) (Long-Term Investment in Vendor, USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Long-Term Investment in Vendor
Significant Accounting Policies [Line Items]
Total related party expense	$4.30	$1.30
Total amount payable to related parties	$1.60		$1.30

ACQUISITIONS_Narrative_Details

ACQUISITIONS - Narrative (Details) (USD $)	0 Months Ended
	Jan. 23, 2015	Jan. 13, 2015	Mar. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill			$230,147,000	$198,049,000
webOMR
Business Acquisition [Line Items]
Payments to Acquire Software	22,000,000
Contingent consideration, value	18,000,000
RazorInsights
Business Acquisition [Line Items]
Payments to acquire businesses, gross		40,200,000
Fair value of assets acquired	8,100,000
Goodwill		32,100,000
Transaction costs associated with the acquisition	300,000
RazorInsights | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired	7,000,000
RazorInsights | Customer Relationships
Business Acquisition [Line Items]
Intangible assets acquired	$4,000,000

NET_LOSS_INCOME_PER_SHARE_Sche

NET (LOSS) INCOME PER SHARE - Schedule of Earnings Per Share, Basic and Diluted (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Net loss	($8,832)	($8,055)
Weighted average shares used in computing basic and diluted net loss per share (in shares)	38,278	37,484
Net (loss) income per share - basic (in dollars per share)	($0.23)	($0.21)

FAIR_VALUE_OF_FINANCIAL_INSTRU2

FAIR VALUE OF FINANCIAL INSTRUMENTS - Narrative (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amount outstanding on facility	$95,000,000	$0
Amount recognized in earnings	0
Gain (loss) on interest rate cash flow hedge ineffectiveness	0
Pre-tax unrealized gain (loss) included in AOCI	-400,000
Long-term U.S. government backed securities	0
Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate swap liability	-615,000	-244,000
Fair Value, Measurements, Recurring | Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate swap liability	0	0
Fair Value, Measurements, Recurring | Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate swap liability	-615,000	-244,000
MDP Accelerator portfolio | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	750,000	750,000
MDP Accelerator portfolio | Fair Value, Measurements, Recurring | Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	750,000	750,000
MDP Accelerator portfolio | Fair Value, Measurements, Recurring | Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	0	0
Senior Credit Facility | Unsecured Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans Payable to Bank	170,000,000
Amount outstanding on facility		173,800,000
Senior Credit Facility | Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amount outstanding on facility	$95,000,000	$35,000,000

FAIR_VALUE_OF_FINANCIAL_INSTRU3

FAIR VALUE OF FINANCIAL INSTRUMENTS - Financial Assets and Liabilities that Are Measured at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Marketable equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investments	$27,160	$40,950
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	27,910	41,700
Interest rate swap liability	615	244
Total liabilities	-615	-244
Fair Value, Measurements, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	27,160	40,950
Interest rate swap liability	0	0
Total liabilities	0	0
Fair Value, Measurements, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Interest rate swap liability	615	244
Total liabilities	-615	-244
Fair Value, Measurements, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	750	750
Interest rate swap liability	0	0
Total liabilities	0	0
Fair Value, Measurements, Recurring | Marketable equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investments	27,160	40,950
Fair Value, Measurements, Recurring | Marketable equity securities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investments	27,160	40,950
Fair Value, Measurements, Recurring | Marketable equity securities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investments	0	0
Fair Value, Measurements, Recurring | Marketable equity securities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investments	0	0
Fair Value, Measurements, Recurring | MDP Accelerator portfolio
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities	750	750
Fair Value, Measurements, Recurring | MDP Accelerator portfolio | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities	0	0
Fair Value, Measurements, Recurring | MDP Accelerator portfolio | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities	0	0
Fair Value, Measurements, Recurring | MDP Accelerator portfolio | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investments		750
Debt securities	$750	$750

FAIR_VALUE_OF_FINANCIAL_INSTRU4

FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) (Fair Value, Measurements, Recurring, Level 3, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Fair Value, Measurements, Recurring | Level 3
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$750
Reductions	0
Additions	0
Ending balance	$750

INVESTMENTS_Summary_of_Availab

INVESTMENTS - Summary of Available-For-Sale Securities (Details) (Marketable equity securities, USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Marketable equity securities
Schedule of Available-for-sale Securities [Line Items]
Cost	$1,100	$1,100
Gross Unrealized Gain	26,060	39,850
Fair Value	$27,160	$40,950